NuGenerex Immuno-Oncology, Inc.
NUGX
Other OTC0.00
USD
- -
- -
CIK
0001804585
ISIN
US67053X1028
CUSIP
67053X102
Return %
Stock
S&P500
1Y
- -
18.99
3Y
-100.00
64.75
5Y
-100.00
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Joseph Moscato
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10102 USA Today Way Miramar FL United States of America 33025
- IPO Date
- Mar 15, 2021
- CIK
- 0001804585
- Website
- generex.com
- Similar Companies
- Business
- NuGenerex Immuno-Oncology, Inc. (NUGX) is a biotechnology company focused on modulating the immune system and activating T cells to treat cancer and infectious diseases through its patented Ii-Key platform technology. The Ii-Key peptide, derived from the MHC Class II associated invariant chain, enhances antigen presentation and T-cell immune responses; the company develops immunotherapeutic vaccines including its lead candidate AE37, an Ii-Key-HER2 peptide vaccine in Phase II trials for HER2-positive breast, prostate, ovarian, bladder, and pancreatic cancers, as well as Ii-Key-GP100 for melanoma in preclinical and Phase I-ready stages, and exploratory Ii-Key vaccines targeting tumor-associated antigens and neoantigens for personalized cancer therapies. It also pursues Ii-Key-based vaccines for infectious diseases, including SARS-CoV-2 epitopes advancing toward clinical trials. Founded in 1993 and headquartered in Miramar, Florida, the company operates primarily in the United States with historical clinical development partnerships such as the licensing agreement with Shenzhen Bioscien for AE37 in prostate cancer and combination studies with pembrolizumab for triple-negative breast cancer; recent efforts include a planned spin-out from Generex Biotechnology via merger with a public vehicle and Kiromic BioPharma to expand immunotherapy platforms like CAR-T and CAR-NK, alongside a closed $50 million equity financing facility in 2020 to fund clinical advancement and strategic growth.